arrow
L

Luis M. Vence

university of texas system
H指数:38
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

肠道菌群特征与联合CTLA-4和PD-1阻断的毒性有关

2021-07-08251
OAAI
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

ipilimumab治疗前列腺癌患者后的新抗原反应,免疫相关性和有利结果

2020-04-01116
PREAI
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

帕博利珠单抗在复发性胶质母细胞瘤患者中的机会之窗临床试验揭示了免疫抑制性巨噬细胞的优势

2019-11-22114
OAAI
Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome
2019-07-013
PRE
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

黑色素瘤和胰腺癌中免疫浸润的比较突出了VISTA作为胰腺癌的潜在靶标

2019-01-11260
OA
The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM)
2018-07-010
PRE
Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application
2018-07-013
PRE
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
2017-10-02164
OAAI
Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
2017-07-015
PRE
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

VISTA是前列腺癌患者ipilimumab治疗后增加的抑制性免疫检查点

2017-03-27522
OAAI
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

系统循环中CD8 T细胞的克隆扩增先于ipilimumab诱导的毒性的发展

2016-10-03192
OAAI
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
2016-08-01799
OAAI